CN115244068A - 铁蛋白-ace-2短肽纳米药物 - Google Patents
铁蛋白-ace-2短肽纳米药物 Download PDFInfo
- Publication number
- CN115244068A CN115244068A CN202180018913.4A CN202180018913A CN115244068A CN 115244068 A CN115244068 A CN 115244068A CN 202180018913 A CN202180018913 A CN 202180018913A CN 115244068 A CN115244068 A CN 115244068A
- Authority
- CN
- China
- Prior art keywords
- ferritin
- acid sequence
- amino acid
- protein
- fusion protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 65
- 239000003814 drug Substances 0.000 title claims description 23
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 89
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 89
- 241000711573 Coronaviridae Species 0.000 claims abstract description 65
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 claims abstract description 58
- 239000002105 nanoparticle Substances 0.000 claims abstract description 58
- 230000027455 binding Effects 0.000 claims abstract description 36
- 102100031673 Corneodesmosin Human genes 0.000 claims abstract description 32
- 101710139375 Corneodesmosin Proteins 0.000 claims abstract description 31
- 241000700605 Viruses Species 0.000 claims abstract description 23
- 101710167605 Spike glycoprotein Proteins 0.000 claims abstract description 17
- 101710114810 Glycoprotein Proteins 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 13
- 230000000754 repressing effect Effects 0.000 claims abstract description 3
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 claims abstract 18
- 238000008416 Ferritin Methods 0.000 claims description 130
- 108050000784 Ferritin Proteins 0.000 claims description 128
- 102000008857 Ferritin Human genes 0.000 claims description 128
- 150000001413 amino acids Chemical group 0.000 claims description 102
- 108090000623 proteins and genes Proteins 0.000 claims description 99
- 102000004169 proteins and genes Human genes 0.000 claims description 80
- 235000018102 proteins Nutrition 0.000 claims description 72
- 239000000178 monomer Substances 0.000 claims description 59
- 150000007523 nucleic acids Chemical class 0.000 claims description 24
- 210000004027 cell Anatomy 0.000 claims description 19
- 210000004899 c-terminal region Anatomy 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 18
- 102000039446 nucleic acids Human genes 0.000 claims description 18
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 claims description 14
- 208000015181 infectious disease Diseases 0.000 claims description 14
- 241000588724 Escherichia coli Species 0.000 claims description 13
- 235000001014 amino acid Nutrition 0.000 claims description 12
- 230000001580 bacterial effect Effects 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 12
- 101710157275 Ferritin subunit Proteins 0.000 claims description 8
- 206010035664 Pneumonia Diseases 0.000 claims description 8
- 239000002773 nucleotide Substances 0.000 claims description 8
- 125000003729 nucleotide group Chemical group 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000005557 antagonist Substances 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 7
- 101000868165 Acidianus ambivalens Sulfur oxygenase/reductase Proteins 0.000 claims description 6
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 6
- 102000012751 Pyruvate Dehydrogenase Complex Human genes 0.000 claims description 6
- 108010090051 Pyruvate Dehydrogenase Complex Proteins 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- 241000315672 SARS coronavirus Species 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 235000018417 cysteine Nutrition 0.000 claims description 4
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- DPGCCPXHQRGEBE-UHFFFAOYSA-N 4a,5,6,7-tetrahydro-1H-pteridine-2,4-dione Chemical compound N1C(NC(C2NCCN=C12)=O)=O DPGCCPXHQRGEBE-UHFFFAOYSA-N 0.000 claims description 3
- 241000710929 Alphavirus Species 0.000 claims description 3
- 241001502567 Chikungunya virus Species 0.000 claims description 3
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims description 3
- 230000002860 competitive effect Effects 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 108020004705 Codon Proteins 0.000 claims description 2
- 208000001528 Coronaviridae Infections Diseases 0.000 claims description 2
- 241000283073 Equus caballus Species 0.000 claims description 2
- 241000590002 Helicobacter pylori Species 0.000 claims description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 2
- 241001529936 Murinae Species 0.000 claims description 2
- 241000205156 Pyrococcus furiosus Species 0.000 claims description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 2
- 102000005421 acetyltransferase Human genes 0.000 claims description 2
- 108020002494 acetyltransferase Proteins 0.000 claims description 2
- 235000004279 alanine Nutrition 0.000 claims description 2
- 238000010353 genetic engineering Methods 0.000 claims description 2
- 235000013922 glutamic acid Nutrition 0.000 claims description 2
- 239000004220 glutamic acid Substances 0.000 claims description 2
- 229940037467 helicobacter pylori Drugs 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121649 protein inhibitor Drugs 0.000 claims description 2
- 239000012268 protein inhibitor Substances 0.000 claims description 2
- 210000000952 spleen Anatomy 0.000 claims description 2
- -1 mercaptooctanoyl Chemical group 0.000 claims 2
- 102000004357 Transferases Human genes 0.000 claims 1
- 108090000992 Transferases Proteins 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000004973 liquid crystal related substance Substances 0.000 claims 1
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 description 40
- 239000000523 sample Substances 0.000 description 27
- 239000013612 plasmid Substances 0.000 description 24
- 239000000243 solution Substances 0.000 description 14
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 239000006228 supernatant Substances 0.000 description 10
- 238000005406 washing Methods 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 8
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 230000000903 blocking effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000002245 particle Substances 0.000 description 8
- 102000005962 receptors Human genes 0.000 description 8
- 108020003175 receptors Proteins 0.000 description 8
- 101710185050 Angiotensin-converting enzyme Proteins 0.000 description 7
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 7
- 229960000723 ampicillin Drugs 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 239000006166 lysate Substances 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 208000025721 COVID-19 Diseases 0.000 description 5
- 101000929928 Homo sapiens Angiotensin-converting enzyme 2 Proteins 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 108010033276 Peptide Fragments Proteins 0.000 description 5
- 102000007079 Peptide Fragments Human genes 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 102000048657 human ACE2 Human genes 0.000 description 5
- 229940126585 therapeutic drug Drugs 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 241001678559 COVID-19 virus Species 0.000 description 4
- 108700010070 Codon Usage Proteins 0.000 description 4
- 238000001976 enzyme digestion Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000012160 loading buffer Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 102000000546 Apoferritins Human genes 0.000 description 3
- 108010002084 Apoferritins Proteins 0.000 description 3
- 241001052560 Thallis Species 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000004153 renaturation Methods 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 239000013049 sediment Substances 0.000 description 3
- 238000012772 sequence design Methods 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 241000024188 Andala Species 0.000 description 2
- 244000309467 Human Coronavirus Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 102100028298 Vacuolar protein sorting-associated protein VTA1 homolog Human genes 0.000 description 2
- 101710111280 Vacuolar protein sorting-associated protein VTA1 homolog Proteins 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 229940124272 protein stabilizer Drugs 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000001338 self-assembly Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- GNJRUICIDVRSDL-UHFFFAOYSA-N 8-sulfanyloctanamide Chemical compound NC(=O)CCCCCCCS GNJRUICIDVRSDL-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 101710106940 Iron oxidase Proteins 0.000 description 1
- 102000004901 Iron regulatory protein 1 Human genes 0.000 description 1
- 108090001025 Iron regulatory protein 1 Proteins 0.000 description 1
- 101800001509 Large capsid protein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000005496 eutectics Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 239000000863 peptide conjugate Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000012807 shake-flask culturing Methods 0.000 description 1
- 230000005476 size effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明提供了一种RBD/ACE2阻遏肽，所述RBD/ACE2阻遏肽能够阻遏新冠状肺炎病毒(SARS‑CoV‑2)表面刺突糖蛋白(S蛋白)与血管紧张素转化酶2(ACE‑2)结合，具有与新型冠状肺炎病毒(SARS‑CoV‑2)的S蛋白的结合亲和性。本发明还提供了包含所述RBD/ACE2阻遏肽的融合蛋白、包含所述融合蛋白的纳米颗粒。本发明的RBD/ACE2阻遏肽、融合蛋白、纳米颗粒可用于预防和/或治疗冠状病毒科病毒引起的疾病。
Description
PCT国内申请，说明书已公开。
Claims (14)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020105045767 | 2020-06-05 | ||
| CN202010504576 | 2020-06-05 | ||
| PCT/CN2021/098204 WO2021244623A1 (zh) | 2020-06-05 | 2021-06-03 | 铁蛋白-ace-2短肽纳米药物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115244068A true CN115244068A (zh) | 2022-10-25 |
Family
ID=78830133
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180018913.4A Pending CN115244068A (zh) | 2020-06-05 | 2021-06-03 | 铁蛋白-ace-2短肽纳米药物 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN115244068A (zh) |
| WO (1) | WO2021244623A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112851825A (zh) * | 2021-02-10 | 2021-05-28 | 军事科学院军事医学研究院军事兽医研究所 | 表达新型冠状病毒rbd的重组铁蛋白纳米颗粒及其构建方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108976299B (zh) * | 2017-06-05 | 2020-02-14 | 昆山新蕴达生物科技有限公司 | 一种改善抗体片段亲和力和体内半衰期的方法 |
| CN108379240B (zh) * | 2018-03-09 | 2020-09-08 | 华东理工大学 | 抗EGFR scFv::FTH1/FTH1蛋白纳米粒子在制备药物中的应用 |
-
2021
- 2021-06-03 CN CN202180018913.4A patent/CN115244068A/zh active Pending
- 2021-06-03 WO PCT/CN2021/098204 patent/WO2021244623A1/zh active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021244623A1 (zh) | 2021-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2693145B2 (ja) | 乳頭腫ウイルス型特異的抗体 | |
| JP5902679B2 (ja) | ＩＬ−４Ｒαに結合する涙液リポカリンムテイン | |
| WO2021184415A1 (zh) | 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白单区域亚单位纳米疫苗 | |
| CN113121704B (zh) | 基于纳米颗粒的冠状病毒疫苗 | |
| JPH11502416A (ja) | 診断、予防および治療のための多発性硬化症に関与するウイルス性物質およびヌクレオチドフラグメント | |
| CN113512096A (zh) | 一种鲈鱼弹状病毒重组g2蛋白及其应用 | |
| CN109021086B (zh) | 一种抗菌肽天蚕素a突变体及其编码基因、制备方法和应用 | |
| WO2021174567A1 (zh) | 一种基于细菌复合物的新型冠状病毒s蛋白双区域亚单位纳米疫苗 | |
| CN115244068A (zh) | 铁蛋白-ace-2短肽纳米药物 | |
| CN111875676A (zh) | 非洲猪瘟病毒免疫原的p49突变蛋白、重组载体、大肠杆菌基因工程菌及制备方法和应用 | |
| CN113403329B (zh) | 一种用于猫冠状病毒的rna疫苗及其构建方法 | |
| JP7229169B2 (ja) | 生体高分子の精製のための超分子高アフィニティタンパク質結合系 | |
| JPH03503843A (ja) | ホスホリパーゼａ２の精製方法およびホスホリパーゼａ２様ポリペプチドの製造方法 | |
| CN110157655B (zh) | 一种无毒性气肿疽梭菌基因工程亚单位疫苗用菌种及其应用 | |
| CN113621598A (zh) | 钙蛋白酶-1在抵抗猪流行性腹泻病毒感染中的应用 | |
| CN112941058B (zh) | 一种重组溶组织梭菌ii型胶原酶及其制备方法和应用 | |
| JP2001527383A (ja) | 結核菌の細胞内取り込みをコードするｄｎａ分子断片およびその使用 | |
| WO2021233244A1 (zh) | 基于铁蛋白重链亚基的缀合物及其应用 | |
| CN114230671B (zh) | 寨卡病毒重组蛋白疫苗及其制备方法 | |
| CN116854786B (zh) | 一种高效杀伤产肠毒素脆弱拟杆菌的细菌素及其应用 | |
| CN109942718B (zh) | 一种无毒性破伤风毒素和产气荚膜梭菌β毒素重组融合蛋白 | |
| JP2024521368A (ja) | 環状ＲＮＡ Ｃｉｒｃ－ＡＣＥ２翻訳によるポリペプチド及びその使用 | |
| WO2002053590A1 (fr) | Nouvelle enzyme fibrinolytique, polynucleotide codant ce polypeptide et utilisation correspondante | |
| CN104789585B (zh) | 一种在大肠杆菌中生产抗血管剂rt‑x的方法及其应用 | |
| JP6399589B2 (ja) | 肺炎球菌における発現プロモーター |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |